U.S. stock futures were higher this morning, with the Dow futures gaining around 1,000 points on Monday.

Shares of Valneva SE (NASDAQ:VALN) fell sharply in pre-market trading.

Pfizer (NYSE:PFE) and Valneva disclosed topline results from Phase 3 VALOR clinical trial of investigational 6-Valent OspA-based Lyme disease vaccine candidate PF-0730740.

Valneva shares dipped 14% to $8.88 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• LiveWire Group Inc (NASDAQ:LVWR) shares dipped 14.6% to $1.04 in pre-market trading after dipping 10% on Friday.
• Anghami Inc (NASDAQ:ANGH) declined 14.3% to $2.40 in pre-market trading after dipping 12% on Friday.
• Golar LNG Ltd (NASDAQ:GLNG) fell 11% to $46.90 in pre-market trading.
• Kosmos Energy Ltd (NYSE:KOS) fell 10.2% to $2.55 in pre-market trading.
• Swarmer Inc (NASDAQ:SWMR) declined 9.3% to $33.30 in pre-market trading.
• Equinor ASA (NYSE:EQNR) fell 8.2% to $38.21 in pre-market trading.
• CF Industries Holdings, Inc. (NYSE:CF) fell 7.1% to $116.00 in pre-market trading.
• Venture Global Inc (NYSE:VG) fell 7% to $14.70 in pre-market trading. Venture Global and Vitol reported a new LNG purchase agreement.
• SM Energy Co (NYSE:SM) fell 5.1% to $28.50 in pre-market trading.
• PepGen Inc (NASDAQ:PEPG) fell 5.1% to $4.46 in pre-market trading. PepGen recently reported fourth-quarter financial results. The FDA placed a partial hold on the company’s FREEDOM2-DM1 Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.